Notice of Allowance for Key US Exenatide Patent
Filed with ASX · · 2 pages · English
Invex Therapeutics Ltd. on 6ix
Earlier from Invex Therapeutics
- Phase II Clinical Results and Capital Raising Presentation
- Succesful $26 million Share Placement
- Exenatide Meets Key Endpoints in IIH Clinical Trial
- Appendix 4D and Half-year Report
- Phase II Recruitment Completed
Later from Invex Therapeutics
- Initial FDA and EMA Advice on Presendin Development
- Quarterly Report and Appendix 4C
- Quarterly Report and Appendix 4C with appendix
- Invex Provides Development Update
- Investor Presentation
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics